In a report released on May 12, Alistair Campbell from RBC Capital maintained a Buy rating on Pharming Group (PHGUF – Research Report), with a price target of EUR1.80. The company’s shares closed yesterday at $1.17.
According to TipRanks, Campbell is a 4-star analyst with an average return of 11.6% and a 63.64% success rate.
Currently, the analyst consensus on Pharming Group is a Moderate Buy with an average price target of $1.96.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $1.59 and a one-year low of $0.69. Currently, Pharming Group has an average volume of 1,897.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
Read More on PHGUF:
